强迫症的药物治疗现状。
Current trends in drug treatment of obsessive-compulsive disorder.
机构信息
Department of Internal Medicine, Division of Clinical Pharmacology.
出版信息
Neuropsychiatr Dis Treat. 2010 May 25;6:233-42. doi: 10.2147/ndt.s3149.
Abstract
This article aims to highlight current trends in the pharmacologic management of obsessive-compulsive disorder (OCD). A systematic search of the electronic database MEDLINE was conducted. The first case report of clomipramine efficacy in the management OCD more than 40 years ago gave new hope for the treatment of this debilitating disorder. Selective serotonin reuptake inhibitors (SSRIs) proved to have a similar efficacy profile compared with clomipramine but had a superior tolerability profile. While many patients with OCD respond to SSRIs or clomipramine, the treatment of those with refractory OCD remains challenging. Different augmentation agents in treatment-resistant OCD have been explored, with antipsychotic agents having the largest supporting evidence base. Nevertheless, new pharmacologic treatment options are required and are under investigation.
摘要
本文旨在强调强迫症（OCD）药物治疗的当前趋势。对电子数据库 MEDLINE 进行了系统搜索。40 多年前，首例氯米帕明治疗 OCD 的病例报告为这种使人衰弱的疾病的治疗带来了新的希望。选择性 5-羟色胺再摄取抑制剂（SSRIs）与氯米帕明相比具有相似的疗效，但具有更好的耐受性。虽然许多 OCD 患者对 SSRIs 或氯米帕明有反应，但治疗难治性 OCD 仍然具有挑战性。已经探索了治疗抵抗性 OCD 中的不同增效剂，抗精神病药物具有最大的支持证据基础。然而，需要并正在研究新的药物治疗选择。
相似文献
1
Current trends in drug treatment of obsessive-compulsive disorder.强迫症的药物治疗现状。
Neuropsychiatr Dis Treat. 2010 May 25;6:233-42. doi: 10.2147/ndt.s3149.
2
A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.选择性5-羟色胺再摄取抑制剂治疗强迫症的疗效综述。
J Clin Psychiatry. 1999 Feb;60(2):101-6. doi: 10.4088/jcp.v60n0206.
3
Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.系统评价与荟萃分析：选择性5-羟色胺再摄取抑制剂与氯米帕明在儿童强迫症中的早期治疗反应
J Am Acad Child Adolesc Psychiatry. 2016 Oct;55(10):851-859.e2. doi: 10.1016/j.jaac.2016.07.768. Epub 2016 Aug 4.
4
Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment.巴西强迫谱系障碍研究联合会成人强迫症治疗指南。第一部分：药物治疗。
Braz J Psychiatry. 2023 May 11;45(2):146-161. doi: 10.47626/1516-4446-2022-2891.
5
Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.5-羟色胺-去甲肾上腺素再摄取抑制剂治疗强迫症：一项批判性综述
J Clin Psychiatry. 2006 Apr;67(4):600-10. doi: 10.4088/jcp.v67n0411.
6
A benzisothiazole derivative and antipsychotic agent, perospirone, for augmentation of selective serotonin reuptake inhibitors (SSRIs) in refractory obsessive-compulsive disorder (OCD): two patient case series.苯并异噻唑衍生物和抗精神病药哌罗匹隆，用于增强难治性强迫症（OCD）的选择性 5-羟色胺再摄取抑制剂（SSRIs）：两项患者病例系列。
Int J Psychiatry Clin Pract. 2006;10(2):142-5. doi: 10.1080/13651500500487586.
7
Pharmacologic therapy of obsessive compulsive disorder.强迫症的药物治疗
Adv Pharmacol. 1994;30:35-52. doi: 10.1016/s1054-3589(08)60171-4.
8
A review of pharmacologic treatments for obsessive-compulsive disorder.强迫症药物治疗综述。
Psychiatr Serv. 2003 Aug;54(8):1111-8. doi: 10.1176/appi.ps.54.8.1111.
9
Refining treatment approaches in obsessive-compulsive disorder.强迫症治疗方法的优化
Int Clin Psychopharmacol. 1996 Dec;11 Suppl 5:13-22. doi: 10.1097/00004850-199612005-00003.
10
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.一项系统评价：抗精神病药物增效治疗难治性强迫症
Mol Psychiatry. 2006 Jul;11(7):622-32. doi: 10.1038/sj.mp.4001823. Epub 2006 Apr 4.
引用本文的文献
1
Ketogenic Diet as a Nutritional Metabolic Intervention for Obsessive-Compulsive Disorder: A Narrative Review.生酮饮食作为强迫症的营养代谢干预：一项叙述性综述。
Nutrients. 2024 Dec 25;17(1):31. doi: 10.3390/nu17010031.
2
Can miRNA Expression Levels Predict Treatment Resistance to Serotonin Reuptake Inhibitors in Patients with Obsessive-Compulsive Disorder?微小RNA表达水平能否预测强迫症患者对5-羟色胺再摄取抑制剂的治疗抵抗？
Psychiatry Clin Psychopharmacol. 2022 Jun 1;32(2):98-106. doi: 10.5152/pcp.2022.22391. eCollection 2022 Jun.
3
Metabolic syndrome in patients with obsessive-compulsive disorder.强迫症患者的代谢综合征
Front Psychiatry. 2023 Aug 15;14:1164750. doi: 10.3389/fpsyt.2023.1164750. eCollection 2023.
4
Update on Statin Treatment in Patients with Neuropsychiatric Disorders.神经精神疾病患者他汀类药物治疗的最新进展
Life (Basel). 2021 Dec 8;11(12):1365. doi: 10.3390/life11121365.
5
Primary care physician's approach for mental health impact of COVID-19.初级保健医生应对新冠疫情心理健康影响的方法。
J Family Med Prim Care. 2020 Jul 30;9(7):3189-3194. doi: 10.4103/jfmpc.jfmpc_513_20. eCollection 2020 Jul.
6
Attenuation of compulsive-like behavior by fluvoxamine in a non-induced mouse model of obsessive-compulsive disorder.氟伏沙明对非诱导性强迫症小鼠模型强迫样行为的抑制作用
Behav Pharmacol. 2018 Jun;29(4):299-305. doi: 10.1097/FBP.0000000000000348.
7
Clinical Profile and Comorbidity of Obsessive-Compulsive Disorder among Children and Adolescents: A Cross-Sectional Observation in Bangladesh.儿童和青少年强迫症的临床特征与共病情况：孟加拉国的一项横断面观察研究
Psychiatry J. 2016;2016:9029630. doi: 10.1155/2016/9029630. Epub 2016 Dec 14.
8
Paroxetine Can Enhance Neurogenesis during Neurogenic Differentiation of Human Adipose-derived Stem Cells.帕罗西汀可增强人脂肪干细胞神经源性分化过程中的神经发生。
Avicenna J Med Biotechnol. 2016 Oct-Dec;8(4):152-158.
9
Behavioral and Genetic Evidence for GIRK Channels in the CNS: Role in Physiology, Pathophysiology, and Drug Addiction.中枢神经系统中GIRK通道的行为学和遗传学证据：在生理学、病理生理学及药物成瘾中的作用
Int Rev Neurobiol. 2015;123:279-313. doi: 10.1016/bs.irn.2015.05.016. Epub 2015 Jun 22.
10
Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial.托吡酯辅助治疗难治性强迫症：一项随机、双盲、安慰剂对照试验。
J Res Med Sci. 2014 Oct;19(10):976-81.
本文引用的文献
1
The PANDAS subgroup of tic disorders and childhood-onset obsessive-compulsive disorder.抽动障碍和儿童起病的强迫症的 PANDAS 亚组。
J Psychosom Res. 2009 Dec;67(6):547-57. doi: 10.1016/j.jpsychores.2009.07.004.
2
Cross-species models of OCD spectrum disorders.强迫症谱系障碍的跨物种模型。
Psychiatry Res. 2009 Nov 30;170(1):15-21. doi: 10.1016/j.psychres.2008.07.016. Epub 2009 Oct 9.
3
Obsessive-compulsive disorder: diagnostic and treatment issues.强迫症：诊断与治疗问题
Psychiatr Clin North Am. 2009 Sep;32(3):665-85. doi: 10.1016/j.psc.2009.05.007.
4
A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder.舍曲林与氯米帕明治疗门诊强迫症患者的双盲对照研究。
Eur Psychiatry. 1997;12(2):82-93. doi: 10.1016/S0924-9338(97)89646-0.
5
Obsessive-compulsive disorder.强迫症
Lancet. 2009 Aug 8;374(9688):491-9. doi: 10.1016/S0140-6736(09)60240-3.
6
Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients.喹硫平增强西酞普兰对非难治性强迫症的疗效：一项针对76例患者的随机、双盲、安慰剂对照研究。
J Clin Psychiatry. 2009 Jul;70(7):1001-8. doi: 10.4088/JCP.08m04269. Epub 2009 Jun 2.
7
Disrupting disordered neurocircuitry: treating refractory psychiatric illness with neuromodulation.扰乱紊乱的神经回路：用神经调节治疗难治性精神疾病。
Mayo Clin Proc. 2009 Jun;84(6):522-32. doi: 10.4065/84.6.522.
8
Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder.SSRIs 治疗强迫症的剂量-反应关系的 Meta 分析。
Mol Psychiatry. 2010 Aug;15(8):850-5. doi: 10.1038/mp.2009.50. Epub 2009 May 26.
9
A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.非典型抗精神病药物增强对5-羟色胺再摄取抑制剂（SSRI）难治性强迫症疗效及安全性的长期试验
J Clin Psychiatry. 2009 Jun;70(6):863-8. doi: 10.4088/JCP.08m04369. Epub 2009 May 5.
10
High-dose selective serotonin reuptake inhibitors in OCD: a systematic retrospective case notes survey.强迫症中高剂量选择性 5-羟色胺再摄取抑制剂：一项系统回顾病例报告调查。
J Psychopharmacol. 2010 Oct;24(10):1439-45. doi: 10.1177/0269881109104850. Epub 2009 Apr 7.
Zotero 插件